Pro Forma 2025 Synergized Adjusted EBITDA: $150 million – $170 million; DefenCath 2025 Revenue: $180 million – $200 million
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CorMedix to acquire Melinta Therapeutics for $300M
- CorMedix reports Q2 EPS 28c, consensus 19c
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CorMedix Inc. Advances Pediatric Dialysis Safety with New Clinical Study
- CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention